Latest Breaking News On - Gijs klarenbeek - Page 1 : comparemela.com

Sequana Medical announces additional alfapump data supporting strong and durable clinical

PRESS RELEASE

United statesGijs klarenbeekCian crosbieHealth solutionsCompany or sequanaAmerican consortium for the study of endSequana medicalEuronext brusselsSenior medical advisorChief executive officerMajor adverse eventsPatient preferencePivotal cohortNorth american consortiumEnd stage liver diseaseNorth america

Sequana Medical N : announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission -October 19, 2023 at 01:53 am EDT

REGULATED INFORMATION - INSIDE INFORMATION 19 October 2023, 07:00 am CEST One-year alfapump data from POSEIDON shows safety and.

United statesCian crosbieGijs klarenbeekHealth solutionsCompany or sequanamedicalAmerican consortium for the study of endSequana medicalEuronext brusselsSenior medical advisorChief executive officerMajor adverse eventsPatient preferencePivotal cohortNorth american consortiumEnd stage liver diseaseNorth america

Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study

Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealandHong kongUnited kingdomKaplan meierCian crosbieGijs klarenbeekGuillaume van renterghemCompany or sequanaClinical events committeeLiver internationalEuronext brusselsNorth americanPivotal cohortRoll in cohortChief executive officer

Sequana Medical NV: Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study

Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably

United statesNew zealandHong kongUnited kingdomKaplan meierCian crosbieGijs klarenbeekGuillaume van renterghemCompany or sequanaLiver internationalEuronext brusselsNorth americanPivotal cohortRoll in cohortChief executive officerSequana medical

Sequana Medical announces the completion of alfapump

Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year.

United statesNew zealandHong kongUnited kingdomKaplan meierCian crosbieGijs klarenbeekGuillaume van renterghemCompany or sequanaClinical events committeeLiver internationalSequana medicalEuronext brusselsNorth americanPivotal cohortRoll in cohort